Evidence map›Paper›PMID 21385137›Full record

ArticleNanomedicine (London, England)2011

Cowpea mosaic virus nanoparticles target surface vimentin on cancer cells.

Nicole F Steinmetz, Choi-Fong Cho, Amber Ablack, John D Lewis, Marianne Manchester

Abstract read
In one paragraph

Article in Nanomedicine (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 118 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Nicole F SteinmetzDepartment for Cell Biology, Center for Integrative Molecular Biosciences, The Scripps Research Institute, La Jolla, CA, USA.
Choi-Fong Cho
Amber Ablack
John D Lewis
Marianne Manchester
Western University · CAUniversity of California, San Diego · US

Funding

USING VIRAL NANOPARTICLES TO TARGET CANCERR01CA112075 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MANCHESTER, MARIANNE · 2005 to 2009
$3.7M
Viral nanoparticles as platforms for the design of novel targeted therapeuticsK99EB009105 · NIBIB · SCRIPPS RESEARCH INSTITUTE, THE · PI STEINMETZ, NICOLE FRANZISKA · 2009 to 2010
$97k
CIHR MOP-84535NCI NIH HHS R01 CA112075NIBIB NIH HHS K99 EB009105
6 · The paper itself

Abstract

aimsVimentin, a type III intermediate filament, is upregulated during epithelial-mesenchymal transition and tumor progression. Vimentin is surface-expressed on cells involved in inflammation; the function remains unknown. We investigated the expression of surface vimentin on cancer cells and evaluated targeting nanoparticles to tumors exploiting vimentin. MATERIALS &

methodsCowpea mosaic virus nanoparticles that interact with surface vimentin were used as probes. Tumor homing was tested using the chick chorioallantoic membrane model with human tumor xenografts. RESULTS & DISCUSSION: Surface vimentin levels varied during cell cycle and among the cell lines tested. Surface vimentin expression correlated with cowpea mosaic virus uptake, underscoring the utility of cowpea mosaic virus to detect invasive cancer cells. Targeting to tumor xenografts was observed; homing was based on the enhanced permeability and retention effect. Our data provide novel insights into the role of surface vimentin in cancer and targeting nanoparticles in vivo.

Indexed as

Cell Membrane PermeabilityAnimalsCell CycleCell Line, TumorChick EmbryoComovirusGene Expression Regulation, NeoplasticHumansNanoparticlesNeoplasmsVimentinVirionVimentin

Identifiers

PMID21385137
PMCPMC3436905
OpenAlexW2159709273

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.